AddLife AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
October 27, 2022 at 01:45 am
Share
AddLife AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was SEK 2,100 million compared to SEK 1,850 million a year ago. Net income was SEK 120 million compared to SEK 138 million a year ago. Basic earnings per share from continuing operations was SEK 0.99 compared to SEK 1.13 a year ago. Diluted earnings per share from continuing operations was SEK 0.98 compared to SEK 1.13 a year ago.
For the nine months, sales was SEK 6,758 million compared to SEK 5,862 million a year ago. Net income was SEK 419 million compared to SEK 541 million a year ago. Diluted earnings per share from continuing operations was SEK 3.45 compared to SEK 4.56 a year ago.
AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
ADDLIFE AB 
